85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC)

20251 citationsJournal Articlebronze Open Access

Authors

Good health and well-being

Published in: Journal of Thoracic Oncology

Volume 20, Issue 3, pp. S62-S63

Field-Weighted Citation Impact: 1.65